MARKET

PTN

PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4510
-0.0290
-6.04%
Opening 10:00 09/20 EDT
OPEN
0.4555
PREV CLOSE
0.4800
HIGH
0.4690
LOW
0.4510
VOLUME
94.85K
TURNOVER
--
52 WEEK HIGH
1.300
52 WEEK LOW
0.3750
MARKET CAP
103.78M
P/E (TTM)
-3.9527
1D
5D
1M
3M
1Y
5Y
Palatin to Present Peptides Platform at the TIDES USA Conference
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced a featu...
PR Newswire - PRF · 5d ago
Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D.,...
PR Newswire · 09/13 11:00
Palatin Announces Presentation at the Eyecelerator@ASCRS Conference
/PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that , P...
PR Newswire - PRF · 07/22 21:28
Cathie Wood's ARK Innovation rises amid market plunge — here's what's working in her fund
Concerns about the Delta variant and another round of economic shutdowns could be scaring investors back into Wood's pandemic-proof stocks.
CNBC.com · 07/19 18:29
Palatin Announces Adjournment of Annual Meeting of Stockholders
/PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on and was adjourned to , has been adjourned until at to allow Palatin to solicit additional proxies for Pro...
PR Newswire - PRF · 07/08 20:15
Thinking about buying stock in ContextLogic, Orphazyme, Marin Software, Xpeng, or Palatin Technologies?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ORPH, MRIN, XPEV, and PTN.
PR Newswire - PRF · 06/29 14:45
Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment
Benzinga · 06/29 13:18
Palatin shares rise after completing PL9643 End-of-Phase 2 meeting with FDA
Palatin Technologies (PTN) announces the completion of an End-of-Phase 2 ((EOP2)) meeting with the U.S. FDA for PL9643 for the treatment of dry eye disease ((DED)).Shares up more than 20% premarket.The EOP2
Seekingalpha · 06/29 11:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTN. Analyze the recent business situations of PALATIN TECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTN stock price target is 2.333 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.69M
% Owned: 19.42%
Shares Outstanding: 230.12M
TypeInstitutionsShares
Increased
32
4.81M
New
20
1.36M
Decreased
17
1.34M
Sold Out
6
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.23%
Pharmaceuticals & Medical Research
-0.66%
Key Executives
Non-Executive Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
No Data
About PTN
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.